Onexio Biosystems LLC

Madison, WI · Medtech · Private

microDUO, a high-throughput screening platform with integrated micro-scale diffusion channels enabling multi-cell-type co-culture for drug discovery and toxicity testing

Grants
$3.3M
4 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
2
2 granted · 0 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Incorporating Phase I/II drug metabolism in HTS via micro scale co-culture$225,000
Federal grant· 1 of 2 same dayDepartment of Health and Human Services · Phase II · Incorporating Phase I/II drug/chemical metabolism in HTS via micro scale co-culture$913,343
Federal grant· 2 of 2 same dayDepartment of Health and Human Services · Phase II · Incorporating Phase I/II drug/chemical metabolism in HTS via micro scale co-culture$1,550,000
Federal grantDepartment of Health and Human Services · Phase II · Incorporating Phase I/II drug/chemical metabolism in HTS via micro scale co-culture$636,657
Federal grant · SBIR/STTR

Peer position

Medtech · 4531 companies · ranked on federal contract value
Medtech companies ranked by federal contract value
#CompanyContractsDisclosed equity
784CLINITECH, LLC——
785AMPHIONIC LLC——
786SynerFuse, Inc.—$6.5M
787Onexio Biosystems LLC——
788Operational Techologies Corporation——
789SUBTLE TECHNOLOGY LLC——
790Nuclein, LLC—$2.5M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 2 granted of 2

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.